Limited value of @entity9229 in @entity699 : a prospective study of a 6-week treatment in 20 XXXX .

@entity1 @entity2013 @entity9229 @entity5 @entity935 @entity699 @entity701
CONTEXT AND OBJECTIVE: The role of @entity9229 in @entity699 ( @entity699 ) remains controversial. The experience is limited to case reports and few open studies that report the effects determined after >= 1 month of treatment. In @entity2013 and @entity935 -responsive GH-secreting @entity5 , effects of @entity9229 are seen within days or weeks. Here, we searched for short-term effects of @entity9229 in @entity699 . DESIGN: Twenty @entity1 (19 na  ve and one recurrent) were included in a prospective study. @entity9229 was administered in increasing doses of 0.5-5mg/week over 6 weeks. METHODS: Urinary free @entity701 (UFC) 24h, morning @entity701 and ACTH, and salivary @entity701 at 0800, 1600 and 2300h were determined once weekly throughout. Diurnal curves (six samples) of serum @entity701 were measured at start and end. RESULTS: At study end, the median @entity9229 dose was 5mg, range 2.5-5mg/week. The prolactin levels, markers of compliance, were suppressed in all @entity1 . During the treatment, @entity699 varied, gradual and dose-dependent reductions were not seen. Five @entity1 had a >50% decrease of UFC, three had a >50% rise of UFC. Salivary @entity701 at 2300h showed a congruent >50% change with UFC in two of the five cases with decreased UFC, and in one of the three cases with increased UFC. One @entity1 with decreases in both UFC and 2300h salivary @entity701 also had a reduction in diurnal serum @entity701 during the course of the study. CONCLUSIONS: @entity9229 seems to be of little value in the management of @entity699 . Only one @entity1 had a response-like pattern. Given the known variability of disease activity in @entity699 , this might represent a chance finding.
